Long-Term Response With Imatinib

Tuesday, March 14, 2017
A large group of international researchers conducted efficacy and safety analyses of long-term use of imatinib in the treatment of chronic myeloid leukemia (CML). They randomly assigned patients with newly diagnosed chronic phase CML to receive either imatinib or interferon alfa plus cytarabine. Long-term analyses (10 or more years of follow-up) included overall survival, response to treatment, and serious adverse events.

The median follow-up was 10.9 years. Among the patients in the imatinib group, the estimated overall survival rate at 10 years was 83.3%. Nearly half the patients (48.3%) who had been randomly assigned to imatinib completed study treatment with imatinib, and 82.8% had a complete cytogenetic response.

Researchers concluded that the efficacy of imatinib persisted over time and that long-term administration of imatinib is not associated with unacceptable cumulative or late toxic effects. The study findings were published in The New England Journal of Medicine and the title of an accompanying editorial was simply "Imatinib Changed Everything." Study findings are available here.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.